Home  > 
  EMA committee recommends marketing approval for Kevzara to treat adult patients with moderately to severely active RA,   April 25, 2017
  EMA committee recommends marketing approval for Biogen’s Spinraza to treat SMA,   April 24, 2017
  uniQure not to seek marketing authorization renewal for Glybera in Europe,   April 22, 2017
  Simulations Plus inks distribution deal with Electrolab India,   April 22, 2017
  Mylan introduces generic Trilafon tablets in US market,   April 21, 2017
  Diplomat Pharmacy to distribute Zejula for women with recurrent epithelial ovarian, fallopian tube/primary peritoneal cancer,   April 21, 2017
  DAON BioSciences to market Dovetail's genome assembly services to researchers in South Korea,   April 18, 2017
  BioreclamationIVT to market Cellaria's novel cancer cell lines, cancer culture media in US & Canada,   April 15, 2017
  RedHill, IntelGenx receive Luxembourg regulatory marketing nod for Rizaport to treat acute migraines,   April 15, 2017
  US FDA grants marketing approval for Philips' whole slide imaging system for digital pathology,   April 14, 2017
  Sonoma Pharma receives UAE regulatory approvals for Pediacyn for atopic dermatitis and Epicyn for scar management,   April 13, 2017
  Valeo Pharma, Zambon enter pact to commercialize Xadago to treat Parkinson's disease in Canada,   April 12, 2017
  23andMe gets US FDA authorization to market direct-to-consumer genetic health risk reports,   April 08, 2017
  Simulations Plus inks distribution pact with Quantum Bio Solutions in South Korea,   April 08, 2017
  Hyundai Pharm seeks South Korean marketing nod for Natesto to treat low testosterone,   April 07, 2017
  Indian pharma brace to scout for digital marketing personnel to engage with clinicians & consumers,   April 07, 2017
  Sayre Therapeutics inks Lutrate Depot License pact with GP Pharm S.A. for India, Sri Lanka, Bangladesh and Nepal,   April 05, 2017
  Mylan expands voluntary worldwide recall of device EpiPen auto-injector,   April 03, 2017
  Shire receives Japanese approval to manufacture & market Intuniv to treat ADHD,   April 01, 2017
  Vanda to buy worldwide license from UCSF to develop and commercialize CFTR activators & inhibitors,   March 31, 2017

Copyright © 2016 Saffron Media Pvt. Ltd |